C-MER Medical Holdings Limited disclosed that it repurchased 0.14 million ordinary shares on the Hong Kong Stock Exchange on 15 July 2026. The shares were acquired at prices ranging from HKD 0.95 to HKD 0.97, for an aggregate consideration of HKD 0.13 million, implying a volume-weighted average price of approximately HKD 0.9593 per share. All repurchased shares will be held as treasury stock.
Prior to the transaction, the company had 1.21 billion issued shares (excluding treasury shares) and 22.23 million treasury shares. Following the buy-back, the issued share count fell by 0.01 % to 1.21 billion, while treasury shares increased to 22.37 million. Total issued shares, including treasury stock, remained unchanged at 1.23 billion.
The repurchase was executed under the mandate approved by shareholders on 20 May 2026, which authorises the company to buy back up to 123.23 million shares. To date, 0.14 million shares, equivalent to 0.01 % of the issued share base at mandate date, have been repurchased under this authorisation.
In accordance with Hong Kong listing rules, C-MER Medical is subject to a moratorium on issuing new shares or disposing of treasury shares until 14 August 2026. The company confirmed that the buy-back complied with all applicable Main Board rules and that there have been no material changes to the related explanatory statement filed on 23 April 2025.
Comments